NCT00838071View on ClinicalTrials.gov

Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplantation

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

July 31, 2004

Study Completion Date

August 31, 2004

Conditions

Hepatitis B, Chronic

Interventions

DRUG

Specific intravenous anti-hepatitis B immunoglobulin

Monthly doses of 5000 IU administered intravenously during 6 consecutive months

Trial Locations (4)

28041

Hospital Universitario 12 de Octubre, Madrid

41013

Hospital Virgen del Rocío, Seville

08035

Hospital Clínic de Barcelona, Barcelona

Hospital Vall d'Hebron, Barcelona

All Listed Sponsors

lead

Instituto Grifols, S.A.

INDUSTRY

NCT00838071 - Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplantation | Biotech Hunter | Biotech Hunter